Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04145349 · ClinicalTrials.gov registry record · Phase 1

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

A Phase 1 study of Desmoplastic Small Round Cell Tumor, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
20
Study locations

NCT04145349 is a Phase 1 study of Desmoplastic Small Round Cell Tumor that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 30 participants, below the 70-participant average among 7 other Desmoplastic Small Round Cell Tumor trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04145349, a Phase 1 study of Desmoplastic Small Round Cell Tumor, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Conditions Studied

Desmoplastic Small Round Cell Tumor

Interventions

  • DRUG Cyclophosphamide
  • DRUG Ramucirumab
  • DRUG Vinorelbine

Study Locations (20)

Other

  • Universitaetsklinikum Hamburg-Eppendorf - Hamburg
  • Kyushu University Hospital - Fukuoka
  • Hospital Universitario Virgen Del Rocio - Seville

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • Children's Hospital of Los Angeles - Los Angeles

District of Columbia

  • Children's National Medical Center - Washington D.C.

Missouri

  • Washington University - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Children's Hospital of Philadelphia (CHOP) - Philadelphia

Victoria

  • Royal Children's Hospital - Parkville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-01-22
Est. Completion 2026-10
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04145349

The ClinicalTrials.gov registry entry for NCT04145349 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 7 other Desmoplastic Small Round Cell Tumor trials with a reported enrollment target (57% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Desmoplastic Small Round Cell Tumor appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT04145349 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT04145349 about?

NCT04145349 is a clinical study titled "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor". This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT...

What is the current status of trial NCT04145349?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-01-22. Estimated completion is 2026-10.

What conditions does trial NCT04145349 study?

This clinical trial studies the following conditions: Desmoplastic Small Round Cell Tumor.

What interventions are being tested in trial NCT04145349?

The interventions under investigation include: Cyclophosphamide (DRUG), Ramucirumab (DRUG), Vinorelbine (DRUG).

Who is sponsoring clinical trial NCT04145349?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04145349 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Desmoplastic Small Round Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Desmoplastic Small Round Cell Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.